Technical Analysis for OXBDF - Oxford Biomedical Lt

Grade Last Price % Change Price Change
B 14.36 -1.64% -0.2400
OXBDF closed down 1.64 percent on Friday, May 7, 2021, on 25 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical OXBDF trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Strong but Oversold Other 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 20 DMA Bearish -1.64%
Narrow Range Bar Range Contraction -1.64%
Older End-of-Day Signals for OXBDF ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1% 2 days ago
Fell Below 20 DMA 2 days ago
Fell Below Previous Day's Low 2 days ago
Down 1 ATR 3 days ago
Down 3% 3 days ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Oxford Biomedical Lt Description

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development include OXB-102 that is in Phase I/IIa study preparation for the treatment of Parkinson's disease; OXB-202, which is in a Phase I/IIa trial preparation for the prevention of corneal graft rejection; and OXB-302, a gene-based cancer immunotherapy product that has completed pre-clinical development for use in the treatment of a range of cancers, as well as OXB-201 that has completed Phase I trial for the treatment of wet age-related macular degeneration and diabetic retinopathy. It is also developing gene-based therapies, such as SAR 422459 that is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869, which is in Phase I/II trial for the treatment of Usher syndrome 1B. The company has partnerships with Novartis, Sanofi, GlaxoSmithKline, Bioverativ, Orchard Therapeutics, GC LabCell, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, and Immune Design. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Partnership Biology Biopharmaceutical Life Sciences Cancers Parkinson's Disease Cancer Immunotherapy Cell Therapy Immunotherapy Graft Fibrosis Imperial Therapy Products Cyst Platform Technology Macular Degeneration Treatment Of Parkinson's Disease Gene Therapy Retina Vector Medical Genetics Cystic Fibrosis Sanofi Bioprocess Central Nervous System Disorders Diabetic Retinopathy Orchard Oxb Virotherapy Genetic Engineering Retinopathy Thk Cell Therapy Products Immunotherapy Product Treatment Of Various Cancers Glaxosmithkline Parkinson's Treatment Of A Range Of Cancers Novartis Applied Genetics Bioprocessing Bioverativ Gene Delivery Stargardt Disease Treatment Of Stargardt Disease Viral Vector

Is OXBDF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 15.49
52 Week Low 8.55
Average Volume 1,627
200-Day Moving Average 12.3168
50-Day Moving Average 14.1329
20-Day Moving Average 14.7423
10-Day Moving Average 14.9025
Average True Range 0.2824
ADX 25.35
+DI 40.4985
-DI 36.6346
Chandelier Exit (Long, 3 ATRs ) 14.6428
Chandelier Exit (Short, 3 ATRs ) 14.5172
Upper Bollinger Band 15.5550
Lower Bollinger Band 13.9296
Percent B (%b) 0.26
BandWidth 11.0254
MACD Line 0.2194
MACD Signal Line 0.2972
MACD Histogram -0.0778
Fundamentals Value
Market Cap 1.18 Billion
Num Shares 82.3 Million
EPS -0.01
Price-to-Earnings (P/E) Ratio -1436.00
Price-to-Sales 10.06
Price-to-Book 6.52
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.3600
Resistance 3 (R3) 14.3600 14.3600 14.3600
Resistance 2 (R2) 14.3600 14.3600 14.3600 14.3600
Resistance 1 (R1) 14.3600 14.3600 14.3600 14.3600 14.3600
Pivot Point 14.3600 14.3600 14.3600 14.3600 14.3600
Support 1 (S1) 14.3600 14.3600 14.3600 14.3600 14.3600
Support 2 (S2) 14.3600 14.3600 14.3600 14.3600
Support 3 (S3) 14.3600 14.3600 14.3600
Support 4 (S4) 14.3600